WRB — W. R. Berkley Corporation

The stock is near the lower end of its 52-week range and below all three major moving averages. Analyst ratings are mixed—7 buy, 17 hold, 6 sell—with a consensus target of $69.44, barely above the current price. The Q2 beat and AM Best upgrade are offset by moderating premium rate increases (3.8%) and worries about pricing discipline in parts of the E&S market.

Underlying revenue has been roughly flat-to-slightly-up: it drifted from $3.03 billion in Q3 2023 to $3.77 billion by Q3 2025, then slipped slightly in late 2025 and early 2026. The FMP data shows a bizarre Q2 2026 revenue print of $6.83 billion, +86% year-over-year, which conflicts with the research brief's reported $3.72 billion and is likely a reporting or accounting artifact. Excluding that, top-line growth is low-single-digit. Earnings quality is healthier: quarterly net income has generally stepped up from about $334 million in Q3 2023 to $452–515 million in 2026 quarters, with EPS trending from $0.82 to $1.15–$1.31. The combined ratio of 90.0, ROE of 18.3%, operating margin of 13.7%, and slightly negative accruals ratio support the idea that reported earnings are backed by real cash generation.

At $68.34, WRB trades at roughly 14.0x TTM EPS versus a 5-year average of 14.45x, and about 14.1x forward EPS using the consensus estimate of $4.86. Price-to-sales of 1.41 is below the 5-year average of 1.73, and the PEG is 1.35. That is fair-to-modestly cheap on both absolute and historical-relative bases, not expensive. The 2.71% dividend yield and 0.29 beta add downside ballast. The deterministic valuation label of 'Neutral vs. its own history' matches my read.

At ~14x TTM EPS, the market is not pricing in meaningful growth; it is pricing in flat-to-slightly-declining earnings. If WRB holds EPS near $5.00 and the multiple simply returns to its 5-year average of ~14.45x, the implied value is around $71–72. A Q3 beat or a quiet hurricane season could justify a modest re-rating; conversely, a catastrophe-heavy quarter or faster pricing deterioration would validate the cautious analyst stance. This is a pay-a-fair-price-for-a-quality-underwriter setup, not a momentum trade.

As of 2026-08-27, RSI(14) stood at 38.51, below neutral but not oversold. Price was -2.78% from its 20-day SMA, -3.86% from its 50-day SMA, and -1.67% from its 200-day SMA, so the short- and intermediate-term trend is down or range-bound within a 52-week range of $62.87–$78.96. Entry-timing implication: wait for either a reclaim of the 50-day near $71 or a test closer to $63–65 support before adding. There is no momentum confirmation yet.

• Elevated interest rates are fueling investment income; WRB's domestic book yield was 4.8% and Q2 net investment income hit a record $419 million.
• P&C pricing rate increases moderated to 3.8%, with competitive pressure in shared/layered property, habitational lines, liquor liability, and reinsurance niches.
• Autumn catastrophe/hurricane season is a major swing factor for the reported combined ratio.
• AM Best upgraded WRB's issuer credit ratings in late June 2026, reinforcing its competitive and balance-sheet position.
• Capital returns—special dividend, 11.1% regular dividend increase, and restored 25 million share buyback—support the total return case.

• Q3 2026 earnings scheduled for October 19, 2026: watch net investment income, rate moderation, and catastrophe losses.
• Integration of Verus Specialty Insurance and Vela Insurance Services into Berkley Meridian could drive expense efficiencies.
• Restored share repurchase authorization and special/regular dividend increases continue to return capital.
• Fed rate trajectory: prolonged higher rates extend the investment-income tailwind; rapid cuts would pressure it.

• Pricing softening and competitive E&S markets could force margin givebacks if WRB loses underwriting discipline.
• Catastrophe losses larger than reserve additions, especially during an active hurricane season.
• Investment income could peak or reverse if interest rates fall faster than the market expects.
• Street is cautious—17 holds and 6 sells mean limited near-term share-price support if earnings disappoint.
• The apparent revenue data anomaly in the FMP file adds uncertainty to headline growth comparisons.

WRB is a high-quality specialty insurer executing well: 90.0 combined ratio, record net investment income, 18.3% ROE, AM Best upgrade, and a shareholder-friendly capital program. At roughly 14x earnings with a neutral-to-cheap historical valuation, the long-term risk/reward is attractive, but softening pricing and weak technicals argue for building the position on weakness rather than chasing strength. This is analysis, not personalized financial advice.

Calculated by applying WRB's 5-year average trailing P/E of 14.45 to consensus next-fiscal-year EPS of $4.86, yielding $70.24. This approach reflects the company's stable low-beta franchise and strong underwriting profitability while making no adjustment for the reported data anomaly or near-term pricing softness.